Company News 

Accelerated FDA review for possible Alzheimer’s drug

Accelerated FDA review for possible Alzheimer’s drug

A potential Alzheimer’s treatment has been granted ‘priority review’ status by America’s medicines regulator, speeding up the approval decision-making process. US-quoted Biogen (US:BIIB) and Tokyo-listed Eisai (TYO:4523) revealed last Friday that the Food and Drug Administration (FDA) had accepted an application for their investigational therapy ‘aducanumab’, with a decision expected by 7 March next year. According to the companies, which have worked together on the development and commercialisation of aducanumab since 2017, the FDA has said that “if possible, it plans to act early on this application”.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now